On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Summit Therapeutics plc (SMMT) Receives Fast Track Designation for Duchenne Muscular Dystrophy

Company: Summit Therapeutics plc (SMMT)
Category: News

Summit Therapeutics plc (NASDAQ: SMMT) was pleased to announce today that the US Food and Drug Administration (‘FDA’) granted Fast Track designation for ezutromid in the treatment of Duchenne Muscular Dystrophy (DMD). Ezutromid is a utrophin modulator and represents a potential disease modifying treatment for all patients with the fatal muscle wasting disease DMD. Advantages of this designation include opportunities for frequent interactions with the FDA during all aspects of development, submission of a New Drug Application (‘NDA’) on a rolling basis, and eligibility for accelerated approval and priority review.

To view the full press release, visit: http://nnw.fm/t43jX

About Summit Therapeutics

Summit Therapeutics is an international biopharmaceutical company focused on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile.  Its goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

About NetworkNewsBreak

NetworkNewsBreak is a rapid summary of a press release that caught the attention of NetworkNewsWire (NNW). NNW provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit https://www.NetworkNewsWire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Contact us: 212.418.1217